Industry News
Perth PDF moves to become a biotech
One of Australia's oldest pooled development funds wants to toss in the towel as an investment vehicle to merge with its most promising holding, Perth biomed Clinical Cell Culture (C3). [ + ]
Diversity will be key to Centre of Excellence success: DeVore
Multi-disciplinary research will be crucial to the success of the Centre for Stem Cell and Tissue Repair, its new chief operating officer told a Melbourne stem cell conference yesterday. [ + ]
Controversies dissuade stem cell researchers, says NIH director
The deputy director for extramural research at the US National Institutes of Health (NIH) warned delegates at a stem cell conference in Melbourne yesterday that the high level of attention being paid to the controversial research was making it difficult to attract scientists to work in the field. [ + ]
NHMRC readies itself for new stem cell laws
National Health and Medical Research Council CEO Prof Alan Pettigrew told a stem cell conference in Melbourne yesterday that the council was already preparing to implement a new embryonic stem cell research and cloning Bill. [ + ]
WA joins global push to detect gravity waves
The High Optical Power project at the recently commenced Australian International Gravitational Observatory near Gingin, in WA, will help scientists harness a million watts of laser power inside supersensitive detectors.
[ + ]pSivida in joint venture with Singapore hospital
The first joint venture equity pact struck by Singapore's largest hospital could open a fast track to market for anti-cancer technology from Perth biotech pSivida. [ + ]
More kudos for Cory
Walter and Eliza Hall Institute director Prof Suzanne Cory has been awarded a Royal Society medal in recognition of her work into the molecular basis for cancer. [ + ]
Genesis announces loss, but ample cash reserves
New Zealand genomics company Genesis Research and Development Corporation has delivered a half-year loss of $NZ5.3 million ($4.57 million), but maintained sufficient cash reserves to support planned research programs. [ + ]
BresaGen to shed nine jobs in wake of failed partnership
Adelaide-based biotechnology company BresaGen has announced nine redundancies and a hiring freeze in the wake of the failed E21R collaboration with British Biotech. [ + ]
Cerylid claims 95 per cent success rate in early screening
Genomics-based drug discovery company Cerylid Biosciences has announced that its lead anti-cancer compound successfully halted the disease in 95 per cent of human cell lines used. [ + ]
Ethics conference hears of therapeutic cloning doubts
Stem cell researcher Prof Alan Trounson would support a moratorium on therapeutic cloning, but says that research into embryonic stem cells is still necessary. [ + ]
Eiffel gains control of R&D arm
Eiffel Technologies has gained full control of its research and development arm in a move that will ensure all future revenue streams flow directly to the drug reformulation company. [ + ]
Market over-reacting to cochlear fears: analysts
A warning on meningitis risk by US cochlear implant manufacturer Advanced Bionics and the Food and Drug Administration last week took its toll on market leader Cochlear. [ + ]
New attack on antibiotic resistant bacteria
Drug discovery company, RiboTargets, in the UK, is mounting a fresh attack on bacteria that cause disease, especially on bacteria that have become resistant to the antibiotics used against them today.
[ + ]Vision Bio chief spells out strategy
Vision BioSystems' recent acquisition of British reagent company Novocastra Laboratories is part of a broader strategy to expand into the global diagnostic instruments market, according to managing director Michael Ohanessian. [ + ]
